Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 9/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.57 |
| ▸ | INSR | P06213 | 3/20 | 0.57 |
| ▸ | IGF1R | P08069 | 3/20 | 0.57 |
| ▸ | ULK1 | O75385 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12892825 | 1.00 | ZAP70 (0.64) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL12729029 | 0.92 | ZAP70 (0.75) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL12729034 | 0.92 | ZAP70 (0.69) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL12729040 | 0.92 | ZAP70 (0.63) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL12729041 | 0.91 | ZAP70 (0.61) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL12729025 | 0.91 | ZAP70 (0.68) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL10209551 | 0.91 | ZAP70 (0.61) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL12729243 | 0.91 | ZAP70 (0.75) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL1912071 | 0.91 | ZAP70 (0.75) | ZAP70ALKINSRIGF1RULK1 | |
| SCHEMBL12781657 | 0.91 | ZAP70 (0.78) | ZAP70ALKINSRIGF1RULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ZAP70 302/4885ALK 3200/4885INSR 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.